for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acorda Therapeutics Inc

ACOR.O

Latest Trade

0.90USD

Change

0.00(0.00%)

Volume

223

Today's Range

--

 - 

--

52 Week Range

0.42

 - 

2.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.90
Open
0.00
Volume
223
3M AVG Volume
122.34
Today's High
--
Today's Low
--
52 Week High
2.78
52 Week Low
0.42
Shares Out (MIL)
47.97
Market Cap (MIL)
40.06
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Acorda Therapeutics Inc Earnings Release

Latest Developments

More

Acorda Therapeutics Says Co Entitled To Receive $15 Million Milestone Payment

Acorda Therapeutics Inc Files For Mixed Shelf Of Upto $100 Mln

Acorda Reports Second Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Industry

Biotechnology & Drugs

Contact Info

420 Saw Mill River Rd

ARDSLEY, NY

10502-2605

United States

+1.914.3474300

http://www.acorda.com

Executive Leadership

John P. Kelley

Non-Executive Independent Chairman of the Board

Ron Cohen

President,Chief Executive Officer, Director

David Lawrence

Chief Business Operations, Principal Accounting Officer

Burkhard Blank

Chief Medical Officer and Head of R&D

Lauren M. Sabella

Chief Commercial Officer

Key Stats

3.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.6K

2018

0.5K

2019

0.2K

2020(E)

0.1K
EPS (USD)

2017

1.750

2018

2.180

2019

-1.720

2020(E)

-1.640
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.25
Price To Book (MRQ)
0.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
77.26
LT Debt To Equity (MRQ)
54.07
Return on Investment (TTM)
-26.19
Return on Equity (TTM)
-23.03

Latest News

Latest News

BRIEF-Acorda Therapeutics Files For Resale Of Up To 8.7 Mln Shares Of Common Stock

* ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 8.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/3ic48dB) Further company coverage:

BRIEF-Acorda Reports First Quarter 2020 Financial Results And Provides Business Update

* ACORDA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Acorda Therapeutics Posts Q4 Earnings Per Share $1.38

* ACORDA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet.

U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet.

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Drugmakers oppose Acorda's bid to block generic MS drug's release

Three generic drug manufacturers are urging a federal appeals court to reject Acorda Therapeutics Inc's "extraordinary" request for an order blocking them from launching a generic version of multiple sclerosis drug Ampyra before the case is decided.

BRIEF-Hls Therapeutics Announces Qtrly Net Loss $0.19 Per Common Share

* QTRLY NET LOSS $0.19 PER COMMON SHARE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Acer Therapeutics Q1 Loss Per Share $0.53

* ACER THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD

BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija

* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up